Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial

Maheswari G Srinivasan, Grace Ndeezi, Cordelia Katureebe Mboijana, Sarah Kiguli, Gabriel S Bimenya, Victoria Nankabirwa, James K Tumwine, Maheswari G Srinivasan, Grace Ndeezi, Cordelia Katureebe Mboijana, Sarah Kiguli, Gabriel S Bimenya, Victoria Nankabirwa, James K Tumwine

Abstract

Background: Pneumonia is a leading cause of children's deaths in developing countries and hinders achievement of the fourth Millennium Development Goal. This goal aims to reduce the under-five mortality rate, by two thirds, between 1990 and 2015.Few studies have examined the impact of zinc adjunct therapy on the outcome of childhood pneumonia. We determined the effect of zinc as adjunct therapy on time to normalization of respiratory rate, temperature and oxygen saturation. We also studied the effect of zinc adjunct therapy on case fatality of severe childhood pneumonia (as a secondary outcome) in Mulago Hospital, Uganda.

Methods: In this double blind, randomized, placebo-controlled clinical trial, 352 children aged 6 to 59 months, with severe pneumonia were randomized to zinc (20 mg for children ≥ 12 months, and 10 mg for those < 12 months) or a placebo once daily for seven days, in addition to standard antibiotics for severe pneumonia. Children were assessed every six hours. Oxygen saturation was normal if it was above 92% (breathing room air) for more than 15 minutes. The respiratory rate was normal if it was consistently (more than 24 hours) below 50 breaths per minute in infants and 40 breaths per minute in children above 12 months of age. Temperature was normal if consistently below 37.5°C. The difference in case fatality was expressed by the risk ratio between the two groups.

Results: Time to normalization of the respiratory rate, temperature and oxygen saturation was not significantly different between the two arms.Case fatality was 7/176 (4.0%) in the zinc group and 21/176 (11.9%) in the placebo group: Relative Risk 0.33 (95% CI 0.15 to 0.76). Relative Risk Reduction was 0.67 (95% CI 0.24 to 0.85), while the number needed to treat was 13. Among HIV infected children, case fatality was higher in the placebo (7/27) than in the zinc (0/28) group; RR 0.1 (95% CI 0.0, 1.0).Among 127 HIV uninfected children receiving the placebo, case fatality was 7/127 (5.5%); versus 5/129 (3.9%) among HIV uninfected group receiving zinc: RR 0.7 (95% CI 0.2, 2.2). The excess risk of death attributable to the placebo arm (Absolute Risk Reduction or ARR) was 8/100 (95% CI: 2/100, 14/100) children. This excess risk was substantially greater among HIV positive children than in HIV negative children (ARR: 26 (95% CI: 9, 42) per 100 versus 2 (95% CI: -4, 7) per 100); P-value for homogeneity of risk differences = 0.006.

Conclusion: Zinc adjunct therapy for severe pneumonia had no significant effect on time to normalization of the respiratory rate, temperature and oxygen saturation. However, zinc supplementation in these children significantly decreased case fatality.The difference in case fatality attributable to the protective effect of zinc therapy was greater among HIV infected than HIV uninfected children. Given these results, zinc could be considered for use as adjunct therapy for severe pneumonia, especially among Highly Active Antiretroviral Therapynaïve HIV infected children in our environment.

Clinical trials registration number: clinicaltrials.gov NCT00373100.

Figures

Figure 1
Figure 1
Study profile.

References

    1. Bryce J, Daelmans B, Dwivedi A, Fauveau V, Lawn JE, Mason E, Newby H, Shankar A, Starrs A, Wardlaw T. Countdown to 2015 for maternal, newborn, and child survival: the 2008 report on tracking coverage of interventions. Lancet. 2008;371:1247–1258.
    1. Bryce J, Boschi-Pinto C, Shibuya K, Black RM-A. WHO estimates the causes of death in children. Lancet. 2005;365:1147–1152. doi: 10.1016/S0140-6736(05)71877-8.
    1. Black RE, Sazawal S. Zinc and childhood infectious disease morbidity and mortality. Br J Nutr. 2001;85:S125–129. doi: 10.1079/BJN2000304.
    1. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lonnerdal B, Ruel MT, Sandtrom B, Wasantwisut E, Hotz C. International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. Food Nutr Bull. 2004;25:S99–203.
    1. WHO. Complementary Feeding of Young Children in Developing Countries: A Review of Current Scientific Knowledge. In Geneva, (WHO/NUT/981); 1998.
    1. Bitarakwate E, Mworozi E, Kekitinwa A. Serum zinc status of children with persistent diarrhoea admitted to diarrhoea unit of Mulago hospital. Afr Health Sci. 2003;3:54–60.
    1. Bimenya GS, Lutalo-Bosa AJ, Nzaro E. Serum zinc reference values in healthy Ugandans (HbAA) East Afr Med J. 1980;57:822–824.
    1. Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebocontrolled trial. Lancet. 2004;363:1683–1688. doi: 10.1016/S0140-6736(04)16252-1.
    1. Bose A, Coles CL, John H, Moses P, Raghupathy P, Kirubakaran C, Black RE, Brooks WA, Santosham M. Efficacy of zinc in the treatment of severe pneumonia in hospitalized children < 2 y old. Am J Clin Nutr. 2006;83:1089–1096. quiz 1207.
    1. Valentiner-Branth P, Shrestha PS, Chandyo RK, Mathisen M, Basnet S, Bhandari N, Adhikari RK, Sommerfelt H, Strand TA. A randomized controlled trial of the effect of zinc as adjuvant therapy in children 2-35 mo of age with severe or nonsevere pneumonia in Bhaktapur, Nepal. Am J Clin Nutr. 2010;91:1667–1674. doi: 10.3945/ajcn.2009.28907.
    1. Tumwesigye N. Master of Paediatrics and Child Health thesis. Makerere Universisty, Kampala; 2000. The prevalence and clinical predictors of hypoxaemia in children admitted to Acute Care Unit Mulago Hospital with Acute Lower Respiratory Tract infections. Print.
    1. Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr. 2004;24:227–235. doi: 10.1179/027249304225019046.
    1. WHO/UNICEF. Handbook on Integrated Management of Childhood Illness. Geneva: WHO; 2000.
    1. Kallander K, Hildenwall H, Waiswa P, Galiwango E, Peterson S, Pariyo G. Delayed care seeking for fatal pneumonia in children aged under five years in Uganda: a case-series study. Bull World Health Organ. 2008;86:332–338. doi: 10.2471/BLT.07.049353.
    1. Hambidge M, Krebs NF. Interrelationships of key variables of human zinc homeostasis: relevance to dietary zinc requirements. Annu Rev Nutr. 2001;21:429–452. doi: 10.1146/annurev.nutr.21.1.429.
    1. QuantichromTM Zinc Assay Kit (DIZN 250)
    1. Thurnham DI. An overview of interactions between micronutrients and of micronutrients with drugs, genes and immune mechanisms. Nutr Res Rev. 2004;17:211–240. doi: 10.1079/NRR200486.
    1. Siberry GK, Ruff AJ, Black RE. Zinc and human immunodeficiency virus infection. Nutr Res. 2002;22:527–538. doi: 10.1016/S0271-5317(02)00364-0.
    1. Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998;68:447S–463S.
    1. Coles CL, Bose A, Moses PD, Mathew L, Agarwal I, Mammen T, Santosham M. Infectious etiology modifies the treatment effect of zinc in severe pneumonia. Am J Clin Nutr. 2007;86:397–403.
    1. Morris SK, Bassani DG, Awasthi S, Kumar R, Shet A, Suraweera W, Jha P. Diarrhea, Pneumonia, and Infectious Disease Mortality in Children Aged 5 to 14 Years in India. PLoS, One. 2011;6:e20119. doi: 10.1371/journal.pone.0020119.
    1. Bassani DG, Kumar R, Awasthi S, Morris SK, Paul VK, Shet A, Ram U, Gaffey MF, Black RE, Jha P, Million Death Study Collaborators. Causes of neonatal and child mortality in India: a nationally representative mortality survey. Lancet. pp. 1853–1860.
    1. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2000;31:170–176. doi: 10.1086/313925.
    1. Strand TA, Briles DE, Gjessing HK, Maage A, Bhan MK, Sommerfelt H. Pneumococcal pulmonary infection, septicaemia and survival in young zinc depleted mice. Br J Nutr. 2001;86:301–306. doi: 10.1079/BJN2001399.
    1. Bao B, Prasad AS, Beck FW, Snell D, Suneja A, Sparker FH, Doshi N, Fitzgerald JT, Swerdlow P. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res. 2008;152:67–80. doi: 10.1016/j.trsl.2008.06.001.
    1. Prasad AS. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis. 2000;182:S62–68. doi: 10.1086/315916.
    1. Brooks WA, Santosham M, Naheed A, Goswami D, Wahed MA, Diener-West M, Faruque AS, Black RE. Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. Lancet. 2005;366:999–1004. doi: 10.1016/S0140-6736(05)67109-7.
    1. Prasad AS. Discovery of human zinc deficiency and studies in an experimental human model. Am J Clin Nutr. 1991;53:403–412.
    1. Chang AB, Torzillo PJ, Boyce NC, White AV, Stewart PM, Wheaton GR, Purdie DM, Wakerman J, Valery PC. Zinc and vitamin A supplementation in Indigenous Australian children hospitalised with lower respiratory tract infection: a randomised controlled trial. Med J Aust. 2006;184:107–112.
    1. Mahalanabis D, Lahiri M, Paul D, Gupta S, Gupta A, Wahed MA, Khaled MA. Randomized, double-blind, placebo-controlled clinical trial of the efficacy of treatment with zinc or vitamin A in infants and young children with severe acute lower respiratory infection. Am J Clin Nutr. 2004;79:430–436.
    1. Nantanda R, Hildenwall H, Peterson S, Kaddu-Mulindwa D, Kalyesubula I, Tumwine JK. Bacterial aetiology and outcome in children with severe pneumonia in Uganda. Ann Trop Paediatr. 2008;28:253–260. doi: 10.1179/146532808X375404.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe